{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:40:28Z","timestamp":1778218828165,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer arising from squamous cells of the epidermis. Most cases of cSCC have a good prognosis if detected and treated early; however, certain cases can be aggressive. The primary risk factor for cSCC is prolonged ultraviolet radiation from sun exposure, leading to DNA mutations. Other risk factors have also been observed, including adverse reactions to medications, particularly immunosuppressants. A query of the Food and Drug Administration Adverse Events Reporting System (FAERS) was done, and all reported events of cSCC as adverse events to medication were recorded along with demographic data of patients affected. A total of 4,792 cases of cSCC as an adverse event to medication were reported between 1997 and 2023. Lenalidomide, a chemotherapeutic drug, had the most cases of cSCC as an adverse event. Nine of the top 10 drugs associated with cSCC had immunosuppressive characteristics. While males had higher odds of cSCC associated with corticosteroids and calcineurin inhibitors, females had higher odds of cSCC related to monoclonal antibodies. Geriatric patients accounted for the majority of cSCC cases at 59.7%. Drawing on data from the FAERS database, there\u2019s been a consistent increase in cSCC cases as a side-effect to certain medications, with most having immunosuppressive characteristics. Since there is a lack of up-to-date literature overviewing the most implicated medications for cSCC, we aimed to illustrate this better, as well as patient demographics, to better guide clinicians when prescribing these medications.<\/jats:p>","DOI":"10.1007\/s00403-024-03109-7","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T07:01:32Z","timestamp":1716620492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA\u2019s adverse events reporting system"],"prefix":"10.1007","volume":"316","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4447-6241","authenticated-orcid":false,"given":"Philippe","family":"Jean-Pierre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyvan","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"issue":"2","key":"3109_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","volume":"78","author":"SKT Que","year":"2018","unstructured":"Que SKT, Zwald FO, Schmults CD (2018) Cutaneous squamous cell carcinoma. J Am Acad Dermatol 78(2):237\u2013247. https:\/\/doi.org\/10.1016\/j.jaad.2017.08.059","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"3109_CR2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","volume":"151","author":"HW Rogers","year":"2015","unstructured":"Rogers HW, Weinstock MA, Feldman SR, Coldiron BM (2015) Incidence Estimate of Nonmelanoma skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012. JAMA Dermatol 151(10):1081. https:\/\/doi.org\/10.1001\/jamadermatol.2015.1187","journal-title":"JAMA Dermatol"},{"key":"3109_CR3","doi-asserted-by":"publisher","unstructured":"Dreyfuss I, Kamath P, Frech F, Hernandez L, Nouri K (2022) Squamous cell carcinoma: 2021 updated review of treatment. Dermatol Ther 35(4). https:\/\/doi.org\/10.1111\/dth.15308","DOI":"10.1111\/dth.15308"},{"issue":"1","key":"3109_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.jidsp.5640173","volume":"4","author":"NM Wikonkal","year":"1999","unstructured":"Wikonkal NM, Brash DE (1999) Ultraviolet Radiation Induced signature mutations in Photocarcinogenesis. J Invest Dermatology Symp Proc 4(1):6\u201310. https:\/\/doi.org\/10.1038\/sj.jidsp.5640173","journal-title":"J Invest Dermatology Symp Proc"},{"issue":"5","key":"3109_CR5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S0190-9622(86)70267-3","volume":"15","author":"SH Yuspa","year":"1986","unstructured":"Yuspa SH (1986) Cutaneous chemical carcinogenesis. J Am Acad Dermatol 15(5):1031\u20131044. https:\/\/doi.org\/10.1016\/S0190-9622(86)70267-3","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3109_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1365-2133.2006.07378.x","volume":"155","author":"C Dang","year":"2006","unstructured":"Dang C, Koehler A, Forschner T et al (2006) E6\/E7 expression of human papillomavirus types in cutaneous squamous cell dysplasia and carcinoma in immunosuppressed organ transplant recipients: HPV expression in cutaneous dysplasia and SCC. Br J Dermatol 155(1):129\u2013136. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07378.x","journal-title":"Br J Dermatol"},{"issue":"6","key":"3109_CR7","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1365-4632.2008.03547.x","volume":"47","author":"D Torchia","year":"2008","unstructured":"Torchia D, Massi D, Caproni M, Fabbri P (2008) Multiple cutaneous precanceroses and carcinomas from combined iatrogenic\/professional exposure to arsenic. Int J Dermatology 47(6):592\u2013593. https:\/\/doi.org\/10.1111\/j.1365-4632.2008.03547.x","journal-title":"Int J Dermatology"},{"issue":"2","key":"3109_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0190-9622(99)70185-4","volume":"40","author":"P Jensen","year":"1999","unstructured":"Jensen P, Hansen S, M\u00f8ller B et al (1999) Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 40(2):177\u2013186. https:\/\/doi.org\/10.1016\/S0190-9622(99)70185-4","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3109_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jaad.2010.11.062","volume":"65","author":"F O\u2019Reilly Zwald","year":"2011","unstructured":"O\u2019Reilly Zwald F, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management. J Am Acad Dermatol 65(2):253\u2013261. https:\/\/doi.org\/10.1016\/j.jaad.2010.11.062","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3109_CR10","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.mayocp.2017.02.015","volume":"92","author":"JG Muzic","year":"2017","unstructured":"Muzic JG, Schmitt AR, Wright AC et al (2017) Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma. Mayo Clin Proc 92(6):890\u2013898. https:\/\/doi.org\/10.1016\/j.mayocp.2017.02.015","journal-title":"Mayo Clin Proc"},{"issue":"S8","key":"3109_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jdv.15967","volume":"33","author":"A Stang","year":"2019","unstructured":"Stang A, Khil L, Kaj\u00fcter H et al (2019) Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents. Acad Dermatol Venereol 33(S8):6\u201310. https:\/\/doi.org\/10.1111\/jdv.15967","journal-title":"Acad Dermatol Venereol"},{"issue":"3","key":"3109_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0300-483X(02)00612-1","volume":"185","author":"T Vial","year":"2003","unstructured":"Vial T (2003) Immunosuppressive drugs and cancer. Toxicology 185(3):229\u2013240. https:\/\/doi.org\/10.1016\/S0300-483X(02)00612-1","journal-title":"Toxicology"},{"issue":"1","key":"3109_CR13","doi-asserted-by":"publisher","first-page":"e000037","DOI":"10.1136\/bmjonc-2023-000037","volume":"2","author":"JM Buchanich","year":"2023","unstructured":"Buchanich JM, Newcomb CW, Washington TL et al (2023) Use of immunosuppression and subsequent cancer incidence: cohort study. Bmjonc 2(1):e000037. https:\/\/doi.org\/10.1136\/Bmjonc-2023-000037","journal-title":"Bmjonc"},{"issue":"3","key":"3109_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0194599818808511","volume":"160","author":"AN Elghouche","year":"2019","unstructured":"Elghouche AN, Pflum ZE, Schmalbach CE (2019) Immunosuppression Impact on Head and Neck cutaneous squamous cell carcinoma: a systematic review with Meta-analysis. Otolaryngol\u2013head neck surg 160(3):439\u2013446. https:\/\/doi.org\/10.1177\/0194599818808511","journal-title":"Otolaryngol\u2013head neck surg"},{"issue":"S8","key":"3109_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/jdv.15843","volume":"33","author":"TJ Willenbrink","year":"2019","unstructured":"Willenbrink TJ, Jambusaria-Pahlajani A, Arron S, Seckin D, Harwood CA, Proby CM (2019) Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma. Acad Dermatol Venereol 33(S8):57\u201360. https:\/\/doi.org\/10.1111\/jdv.15843","journal-title":"Acad Dermatol Venereol"},{"issue":"10","key":"3109_CR16","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.3390\/cancers13102344","volume":"13","author":"E George","year":"2021","unstructured":"George E, Baranwal N, Kang J, Qureshi A, Drucker A, Cho E (2021) Photosensitizing medications and skin Cancer: a Comprehensive Review. Cancers 13(10):2344. https:\/\/doi.org\/10.3390\/cancers13102344","journal-title":"Cancers"},{"key":"3109_CR17","doi-asserted-by":"publisher","unstructured":"Ikeya S, Sakabe J ichi, Yamada T, Naito T, Tokura Y (2018) Voriconazole-induced photocarcinogenesis is promoted by aryl hydrocarbon receptor-dependent COX-2 upregulation. Sci Rep. ;8(1):5050. https:\/\/doi.org\/10.1038\/s41598-018-23439-7","DOI":"10.1038\/s41598-018-23439-7"},{"issue":"1","key":"3109_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jaad.2009.09.033","volume":"62","author":"EW Cowen","year":"2010","unstructured":"Cowen EW, Nguyen JC, Miller DD et al (2010) Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 62(1):31\u201337. https:\/\/doi.org\/10.1016\/j.jaad.2009.09.033","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"3109_CR19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/17460441.2016.1201057","volume":"11","author":"A Kim","year":"2016","unstructured":"Kim A, Cohen MS (2016) The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Expert Opin Drug Discov 11(9):907\u2013916. https:\/\/doi.org\/10.1080\/17460441.2016.1201057","journal-title":"Expert Opin Drug Discov"},{"issue":"3","key":"3109_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1105358","volume":"366","author":"F Su","year":"2012","unstructured":"Su F, Viros A, Milagre C et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366(3):207\u2013215. https:\/\/doi.org\/10.1056\/NEJMoa1105358","journal-title":"N Engl J Med"},{"issue":"4","key":"3109_CR21","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/bjd.15348","volume":"177","author":"JH Wu","year":"2017","unstructured":"Wu JH, Cohen DN, Rady PL, Tyring SK (2017) BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management. Br J Dermatol 177(4):914\u2013923. https:\/\/doi.org\/10.1111\/bjd.15348","journal-title":"Br J Dermatol"},{"issue":"23","key":"3109_CR22","doi-asserted-by":"publisher","first-page":"5830","DOI":"10.3390\/cancers14235830","volume":"14","author":"B Tan","year":"2022","unstructured":"Tan B, Seth I, Fischer O et al (2022) Sex disparity for patients with cutaneous squamous cell carcinoma of the Head and Neck: a systematic review. Cancers 14(23):5830. https:\/\/doi.org\/10.3390\/cancers14235830","journal-title":"Cancers"},{"issue":"19","key":"3109_CR23","doi-asserted-by":"publisher","first-page":"9989","DOI":"10.3390\/ijerph18199989","volume":"18","author":"GJ Adams","year":"2021","unstructured":"Adams GJ, Goldstein EK, Goldstein BG, Jarman KL, Goldstein AO (2021) Attitudes and behaviors that impact skin Cancer risk among men. IJERPH 18(19):9989. https:\/\/doi.org\/10.3390\/ijerph18199989","journal-title":"IJERPH"},{"issue":"2","key":"3109_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/bjd.15324","volume":"177","author":"AC Green","year":"2017","unstructured":"Green AC, Olsen CM (2017) Cutaneous squamous cell carcinoma: an epidemiological review. Br J Dermatol 177(2):373\u2013381. https:\/\/doi.org\/10.1111\/bjd.15324","journal-title":"Br J Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03109-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03109-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03109-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:33:53Z","timestamp":1719387233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03109-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3109"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03109-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3979528\/v1","asserted-by":"object"}]},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"250"}}